With IQVIA MedTech, you gain more than expertise—you gain a partner built for the medical device, diagnostics and digital health industry, dedicated to helping you thrive, every step of the way.
Neurovascular clinical practice can evolve faster than Medical Devices labeling, evidence pathways and reimbursement. For MedTech manufacturers, recurring off-label use may therefore be more than an isolated clinical workaround. In the right circumstances, it can signal unmet need, evidence gaps, access barriers, device-fit limitations or potential lifecycle opportunities.
In this new white paper, Beyond The Label: Turning Neurovascular Clinical Practice into Portfolio Strategy, IQVIA MedTech explores how manufacturers can distinguish isolated clinical activity from recurring signals that warrant further investigation, while maintaining appropriate claims and scientific-exchange boundaries.
What Medical Devices manufacturers can learn
Download the white paper to explore how your teams can:
- Detect emerging signals across literature, claims, registries, field insights, expert centers and KOL feedback.
- Assess clinical and commercial relevance, including clinical rationale, patient need, payer friction, competitive activity and market potential.
- Strengthen governance with appropriate claims controls, surveillance and scientific-exchange boundaries.
- Define evidence requirements, from registries and real-world evidence to PMCF, health-economic evidence and prospective studies.
- Choose the right strategic pathway, whether that means monitoring, further study, device refinement, access strategy, indication expansion, partnership, investment or stopping.
The objective is not to turn every emerging use into an investment opportunity. It is to give MedTech teams a disciplined way to determine which signals are credible, repeatable and strategically relevant.
Click the Contact us button to find out how IQVIA MedTech can support your evidence, access and portfolio strategy.
FAQs
Related solutions
Turn data, strategy, and execution into measurable MedTech market success - faster launches, stronger adoption, and sustained performance.
